Estrella Immunopharma, Inc.
2.4600-0.06 (-2.38%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · ESLA · USD
Key Stats
Market Cap
91.18MP/E (TTM)
-Basic EPS (TTM)
-0.24Dividend Yield
0%Recent Filings
8-K
Nasdaq compliance regained
Estrella Immunopharma regained Nasdaq compliance on September 23, 2025, after letters confirmed its common stock met the $1.00 minimum bid price for 10 straight business days ending September 22. It also satisfied the $35 million market value threshold over 17 consecutive days in the same period. Delisting threats lifted. This stabilizes the stock's trading status amid prior volatility.
10-Q
Q2 FY2025 results
Estrella Immunopharma ramped up its clinical efforts in Q2 FY2025, driving research and development expenses to $4.7 million, up 32% year-over-year from $3.5 million, as the STARLIGHT-1 trial dosed three more patients and activated a second site under the $33 million services agreement with Eureka. Total operating expenses hit $5.5 million, yielding a net loss of $5.5 million, or $0.15 per diluted share on 36.2 million weighted shares—wider than the $4.0 million loss and $0.11 per share last year, with the gap tied to higher clinical milestones while taxes remained negligible at $850. Cash burn eased to $0.9 million for the half-year, bolstered by $1.4 million from a private placement, leaving $1.3 million on hand amid a $7.6 million working capital deficit; the $50 million equity line with White Lion offers a lifeline, though Nasdaq compliance hangs in the balance. Six patients dosed so far. Yet competition from bigger biotech players could squeeze funding further.
8-K
Nasdaq compliance warning issued
Estrella Immunopharma received a Nasdaq notice on August 1, 2025, for failing to maintain a $35 million Market Value of Listed Securities over 30 days from June 13 to July 31, also missing alternative standards. The company has 180 days until January 28, 2026, to hit the threshold for ten straight business days. It plans to monitor and explore options. No immediate delisting impact. Compliance isn't guaranteed.
8-K
Second site activated for EB103 trial
Estrella Immunopharma activated a second clinical site, Baylor Scott & White Research Institute in Dallas, for its ongoing STARLIGHT-1 Phase I/II trial of EB103 T-cell therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma patients. This expansion broadens trial reach and accelerates patient enrollment. Partnering with a top institution advances EB103 development. Trial progress remains on track.
8-K
Estrella raises $3.35M via PIPE
Estrella Immunopharma secured $3.35 million in a private placement on May 30, 2025, issuing 2,233,334 common shares at $1.50 each—50% above the prior day's $1.00 close. Funds will fuel working capital, operations, and the Phase I STARLIGHT-1 trial for EB103 in relapsed/refractory B-cell NHL. A true-up clause promises extra shares if stock dips below $1.50 in 12 months, but needs shareholder nod to dodge Nasdaq limits. This cash infusion bolsters clinical push amid biotech funding squeezes.
BCAB
BioAtla, Inc.
0.70-0.04
BOLT
Bolt Biotherapeutics, Inc.
5.86+0.14
CERO
CERo Therapeutics Holdings, Inc
1.79-0.09
CUE
Cue Biopharma, Inc.
0.69-0.05
EDSA
Edesa Biotech, Inc.
2.07-0.09
FATE
Fate Therapeutics, Inc.
1.34-0.15
LYEL
Lyell Immunopharma, Inc.
16.59-0.12
MBIO
Mustang Bio, Inc.
1.47-0.03
SLS
SELLAS Life Sciences Group, Inc
2.08+0.08
TIL
Instil Bio, Inc.
17.71-1.02